June 8, 2022
Via EDGAR Transmission
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Oxeia Biopharmaceuticals, Inc. Withdrawal of Registration Statement on Form S-1 File No. 333-264301 |
Ladies and Gentlemen:
Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), Oxeia Biopharmaceuticals, Inc. (the “Registrant”) hereby requests the immediate withdrawal of the above-referenced registration statement, together with all exhibits and amendments thereto (the “Registration Statement”). The Registration Statement was initially filed with the Securities and Exchange Commission (the “SEC”) on April 14, 2022.
The Registrant is requesting to withdraw the Registration Statement because it has elected not to pursue the sale of securities pursuant to the Registration Statement at this time. The Registrant confirms that no securities were sold in connection with the offering contemplated by the Registration Statement.
Please direct any questions or comments regarding this correspondence to our counsel, Sean Reid of Sheppard Mullin Richter & Hampton LLP, at (212) 896-0610.
Thank you for your assistance in this matter.
| Very truly yours, | ||
| OXEIA BIOPHARMACEUTICALS, INC. | ||
| /s/ Michael Wyand | ||
| Name: | Dr. Michael Wyand | |
| Title: | Chief Executive Officer | |
| -1- |
